

Epidemiological profile of meningitis following pentavalent vaccination in Iran

Saber Heidari

Hamadan University of Medical Sciences School of Public Health

Manoochehr Karami (✉ man.karami@yahoo.com)

Hamadan University of Medical Sciences <https://orcid.org/0000-0002-9026-3757>

Seyed Mohsen Zahraei

Ministry of Health and Medical Education

Iraj Sedighi

Hamadan University of Medical Sciences Medical School

Fatemeh Azimian Zavareh

Ministerio da Educacao

Research article

Keywords: Haemophilus influenzae, Meningitis, Vaccines, Iran

Posted Date: May 7th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-25359/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Ensuring the effectiveness of the *Haemophilus influenzae type b* (DTwP-Hib-HepB) vaccine in reducing meningitis is an essential approach in evaluating the effectiveness of the vaccine. The study aimed to address the epidemiology of meningitis following pentavalent vaccination in Iran.

Methods

In this descriptive study, data from meningitis patients from 21st March 2011 to 21st July 2018 were extracted from the National Notifiable Diseases Surveillance System. This information was divided into two equal periods before the pentavalent vaccine introduction (21st March 2011 to 17th November 2014) and after the introduction (18th November 2014 to 21st July 2018). Descriptive statistics indices, including frequency, percentages, tables, and graphs, were used to describe the study population.

Results

The number of patients in the study period was 53,174 cases. More than 55% of patients were under five years old. Males (63.34%) were more than females (36.06%). From the clinical point of view, 90.56% had a fever, 57.87% vomited, 53.78% had a headache, and 26.27% had neck stiffness. The death rate was reduced to 2.1%; also, the proportion of confirmed cases caused by *Haemophilus influenzae type b* was 6.7% before the pentavalent vaccine introduction. The corresponding value following vaccine introduction equals to 3.6%. The proportion of children under five has decreased from 4.4–1.9%. This value indicates a 46.2% decrease in the meningitis of all ages and a 57% decrease in children under five due to *Haemophilus influenzae* vaccination.

Conclusions

The results of the study indicate the effectiveness of the vaccine due to changes in meningitis caused by *Haemophilus influenzae type b* after vaccination compared with no vaccination. Therefore, it is advisable to continue the full immunization coverage with the pentavalent vaccine.

Background

Meningitis is a disease caused by inflammation of the protective lining of the brain and spinal cord called meninges [1]. The disease is often caused by viral, bacterial, and fungal infections and is a life-threatening condition that affects about one and a half million people and kills about 170,000 people annually [2, 3]. Untreated meningitis in 50% of cases can lead to severe brain death and injury [4]. The

most common symptoms of the disease include nausea and vomiting, ague, neck stiffness, myalgia (muscle pain), the high fever usually between 39 and 41 degrees, and sensitivity to light [1, 4].

Bacterial meningitis can be caused by a variety of factors, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae*. Failure to receive the *Haemophilus influenzae* vaccine is one of the most important causes of meningitis in children under five years of age [5]. *Haemophilus influenzae* annually results in the deaths of more than 370,000 children under the age of 5 in the world. Given the significant burden of disease caused by these agents, the World Health Organization has recommended adding the *Haemophilus influenzae type b*, Hib vaccine to the countries' immunization program. Like many developing countries and to reduce the number of cases of pneumonia and subsequent meningitis, Iran has added the pentavalent (DTwP-Hib-HepB) vaccine to the routine immunization program at 2, 4 and 6 months old age since 18th November 2014 [6–11].

Concerning the evaluation of vaccine effectiveness from studies, a case-control study in Uganda and the US on children under five years of age reported that the efficacy of the vaccine after injection was more than 93% and 65%, respectively. Another study in Kenya carried out as a cohort, and those receiving the vaccine were considered to have reduced the incidence of meningitis after vaccination from 71 percent to 8 percent. Another study in a randomized trial in India found that the vaccine's effectiveness in protecting meningitis was 94% [12–15].

The constituents of the pentavalent vaccine include *Haemophilus influenzae type b*, hepatitis B, diphtheria, tetanus, and pertussis. The age of vaccination is two, four, and six months [16–18]. Given the recent implementation of the pentavalent vaccination program in the country and the recommendations of the World Health Organization on the periodic evaluation of vaccine effectiveness and despite extensive studies on the efficacy of this vaccine, so far, no studies have been conducted in Iran. There were no studies to evaluate the burden of the disease and the impact of the vaccine on meningitis.

For this reason, an epidemiological study of meningitis from three years and eight months before and three years and eight months after vaccination and comparing the two was one of the critical approaches in evaluating the effectiveness of the pentavalent vaccine. This study aimed to determine the epidemiological profile of meningitis following the pentavalent vaccine was added in Iran.

Methods

This descriptive study was used to describe the epidemiological profile of meningitis in the number of cases from 21st March 2011 to 21st July 2018. All meningitis patient's information including demographic information (age, sex, and occupation), date of disease incidence, geographic area and laboratory information such as biochemical tests, microbiology (culture, gram staining) and serology (latex), final diagnosis, vaccination status, symptoms, and outcome were extracted from the National Notifiable Diseases Surveillance System [19, 20].

In this study, patient information was divided into two equal periods before (21st March 2011 to 17th November 2014), and after vaccination (18th November 2014 to 21st July 2018) and from suspicion aspects, patients were divided into three groups as suspected, probable and confirmed according to the following criteria [21, 22].

Suspected

Anyone at any age with a fever above 38.5 °C and one of the symptoms of neck stiffness, decreased consciousness, meningeal symptoms (headache, vomiting, and any sudden neurological complications), pediatric bulged fontanel suspected case was considered as meningitis case.

Probable

Any suspected case that his cerebrospinal fluid (CSF) test shows at least one of the following:

- Turbid or purulent appearance
- Increased white blood cells more than 100 cells/mm³
- Increased white blood cells 10-100 cells/mm³ plus protein increased above 100 mm/dl or reduced glucose to less than 40 mg/dl
- One of the following results in gram staining:
 1. Gram-negative bacilli (suggestive of *Haemophilus influenzae*)
 2. Gram-negative diplococci (suggested by *Neisseria meningitis*)
 3. Gram-positive diplococci (suggestive of *Streptococcus pneumonia*)

Confirmed

Cases of positive culture or pathogenic mass antigen found in the cerebrospinal fluid or blood of a person with clinical symptoms. After extracting data from the National Notifiable Meningitis Surveillance System, data were entered into Excel software.

Descriptive statistics indices, including mean, frequency, percentages, tables, and graphs were used to describe the study population, and data were analyzed using Stata 14 software. Arc GIS ver 9.3 software was also used to plot the disease status in different parts of the country. The geographical distribution of the confirmed and probable cases of meningitis before and after the pentavalent vaccination was used to obtain data on the population of the country reported on the official website of the Iranian Statistical Center.

The present study has been registered and approved by the Ethics Committee of Hamadan University of Medical Sciences (IR.UMSHA.REC.1397.737).

Results

During the study, 53,174 cases from 1-day to 110-year-old patients with meningitis were enrolled, which 28,471 were pre-vaccinated with the *Haemophilus influenzae type b* vaccine, and 24,703 cases were after vaccination implementation. Also, 40,785 (76.7%) were suspected, 10,574 (19.8%) probable and 1,815 (3.4%) were confirmed.

As Table 1 shows, given the equal number of months before and after immunization, we see a 3,768 decrease in the meningitis cases after vaccination. The number of suspects decreased from 21,541 cases before implementation to 19,244 after implementation. The probable cases decreased from 5,969 to 4,605, and the number of confirmed cases from 961 before the vaccination to 854 after that. Of all probable and confirmed cases of meningitis, 4,468 (36.06%) were female and 7,848 (63.34%) were male and 73 (0.6%) were unknown. The meningitis rate was higher in male cases than females before and after the vaccination program.

Table 1
Basic features of meningitis cases from 21 March 2011 to 22 July 2018

Variable	Categories of variable	Before vaccine integration	After vaccine integration
		N (%)	N (%)
Classification of meningitis cases	Suspected	21541 (75.6)	19244 (77.9)
	Probable	5969 (21.0)	4605 (18.6)
	Confirm	961 (3.4)	854 (3.5)
Sex (probable and confirm)	Male	4376 (63.1)	3472 (63.6)
	Female	2500 (36.0)	1968 (36.1)
	Unknown	54 (0.8)	19 (0.3)
Location (probable and confirm)	Urban	5241 (75.6)	4285 (78.5)
	Rural	1605 (23.2)	1138 (20.8)
	Others	34 (0.5)	17 (0.3)
	Unknown	50 (0.7)	19 (0.4)
Factor (confirm)	<i>Haemophilus influenza</i> (People over 5 years)	22 (2.3)	14 (1.6)
	Streptococcus pneumonia	172 (17.9)	114 (13.3)
	Neisseria meningitis	49 (5.1)	79 (9.3)
	Viral	137 (14.2)	132 (15.5)
	Other things	539 (56.1)	498 (58.3)
	<i>Haemophilus influenza</i> (children under 5 years)	42 (4.4)	17 (1.9)
Occupation (probable and confirm)	Child	3035 (43.8)	2221 (40.7)
	Baby	875 (12.6)	735 (13.5)
	Housewife	702 (10.1)	646 (11.8)
	Student	741 (10.7)	497 (9.1)
	Self employed	596 (8.6)	527 (9.7)
	Unemployed	210 (3.0)	127 (2.3)
	Retired	188 (2.7)	205 (3.8)
	Manual worker	143 (2.1)	91 (1.7)

Variable	Categories of variable	Before vaccine integration	After vaccine integration
		N (%)	N (%)
	Others	440 (6.3)	410 (7.4)
Outcome of the disease	Death	590 (2.7)	461 (2.1)
	Recovery, treatment	20851 (97.3)	20894 (97.9)

Findings showed that out of 12,389 confirmed and probable meningitis cases, 76.89% were in urban areas, 22.26% in rural areas, and 0.41% in nomads and other regions, and information was also 0.5% missed. The proportion of patients in urban areas increased from 75.6–78.5% after vaccination, but the ratio of the rural regions decreased.

Occupational findings show that 55.43% of patients were children under five years and infants, 10.88% housewives, 3.17% retirees, 2.72% unemployed, and the rest were other occupations.

The proportion of meningitis in children under five years before vaccination was 43.8%, which decreased to 40.7% after vaccination, but increased from 12.6–13.5% in infants.

There were 1815 cases of confirmed meningitis, of which 95 (5.2%) were pathogenic *Haemophilus influenzae type b*, 286 (15.7%) were streptococcal pneumonia, 128 (7%) were due to *Neisseria meningitis*, 269 cases (14.8%) were due to viral causes, and 1,037 cases (57.1%) were due to other microorganisms. The number of confirmed cases of meningitis due to *Haemophilus influenzae type b* before the pentavalent vaccine was 64, indicating a 6.7% proportion of this factor compared to the total cases before vaccination, 31 after vaccination. The case has declined to 3.6% of all cases following vaccination. This represents a 46.2% decrease in cases of *Haemophilus influenzae type b* meningitis at all ages compared to before and after vaccine inoculation. Of the 95 cases that were caused by *Haemophilus influenzae type b*, 59 were children under the age of five, in other words, 56% of patients with *Haemophilus influenzae* were children under five years. The reduction in the number of cases in children under five years of age was 57% compared to pre- and post-vaccination, decreasing from 42 to 17, and the proportion of the disease in these children compared to all patients before and after vaccination. 4.4–1.9%.

The number of cases of *Streptococcus pneumonia* decreased from 172 to 114 but increased due to *Neisseria meningitis* (49 to 79). The number of deaths before meningitis was 590 (2.7%) but decreased to 461 (1.2%) after the program.

Comparison of meningitis cases before the vaccination program and after the implementation in the provinces of Iran shows that the number of cases in 26 out of the 31 provinces has decreased.

Results of the study showed that 5697 cases (47.09%) were under five years of age, and 1305 cases (10.79%) were in the age range of 5–10 years. Other cases were older, indicating the importance of

attention being paid to children under five. Comparing the number of meningitis cases under five before and after the vaccination program showed a decrease from 3,075 to 2,622 cases, which is also true in people aged 5–10 and 10–15 years.

The results of this study show that out of 95 confirm patients diagnosed with *Haemophilus influenzae type b*, 91 cases (95.8%) did not receive the *Haemophilus influenzae* vaccine, and only four cases (4.2%) received the vaccine

According to Table 2, 90.7% of patients showed a fever, 57.9% vomiting, 53.8% headache, and 26.3% neck stiffness. Also, Fig. 1 showed, the number of cases of meningitis due to *Haemophilus influenzae type b* has declined significantly in the years following the vaccine.

Table 2
Clinical symptoms of meningitis in Iran from 20 March 2016
to 22 July 2018

Variable	Variable levels	N (%)
Fever	Yes	3081 (90.7)
	No	195 (5.7)
	Unknown	123 (3.6)
Neck stiffness	Yes	893 (26.3)
	No	2114 (62.2)
	Unknown	392 (11.5)
Decreased consciousness	Yes	915 (26.9)
	No	2092 (61.6)
	Unknown	392 (11.5)
Headache	Yes	1828 (53.8)
	No	1137 (33.4)
	Unknown	434 (12.8)
Vomit	Yes	1967 (57.9)
	No	1243 (36.6)
	Unknown	189 (5.5)
Outstanding branding	Yes	141 (4.1)
	No	2848 (83.8)
	Unknown	410 (12.1)
Seizure	Yes	778 (22.9)
	No	2343 (68.9)
	Unknown	278 (8.2)
Kernick	Yes	147 (4.3)
	No	2463 (72.5)
	Unknown	789 (23.2)
Brodzynski	Yes	114 (3.4)
	No	2459 (72.3)

Variable	Variable levels	N (%)
	Unknown	826 (24.3)

According to Figs. 2 and 3, the geographical distribution of confirmed and probable meningitis cases before and after the pentavalent vaccination indicates a significant reduction in meningitis cases based on GIS software.

Discussion

According to the results of this study in all group ages, most cases of meningitis were related to the age group of children under five (55.4%), which confirmed the findings of previous studies. Due to inaccurate registration of children under one, it was not possible to investigate the causes of meningitis in children due to the possibility of changing the pattern of meningitis.

The number of diagnosed meningitis by culture was deficient. In other words, the rate of meningitis with the confirmed diagnosis was 3.4%, and very few patients were diagnosed based on cerebrospinal fluid culture.

Based on the data obtained, the cumulative annual incidence of meningitis caused by *Haemophilus influenza* has been decreasing over the years of study. Also, only 4.2% of the cases with meningitis received the vaccine, and 95.8% did not.

According to a study by Alan Lee, et al. in 2008 in the United States, the results showed that the number of meningitis cases caused by *Haemophilus influenza* in children under five was reduced by 65% after the vaccine. The results of this study are consistent with the current study, which showed a 57% reduction in the number of meningitis cases [13]. Another study conducted in Uganda by Rosamond Lewis on 0- to 59-month-old children reported the efficacy of the *Haemophilus influenza type b* vaccine to reduce the number of meningitis cases, more than 93% [14]. Results of another study in Kenya and India also reported vaccine effectiveness of 89% and 94%, respectively [15]. Another survey by Brangi et al. in Iran also showed a decrease in the incidence of meningitis in the country, and it can be concluded that vaccination has reduced the number of meningitis cases in Iran. Also, the highest number of meningitis cases is in children under five, which is consistent with the results of another study [1].

One of the limitations of this study is the retrospective study and utilization of surveillance system data, which has deficiencies in the data recording, including inadequate registration of patients' age, especially in children under two, and failure to enter information on deaths before diagnosis.

Another limitation of this study was the low number of confirmed cases of meningitis due to the failure of rapid transfer of the specimen to the laboratory and providing the culture conditions that cause only 3.4% of patients had a confirmed diagnosis and the rest of had suspects and probable diagnosis which would

cause errors in the results. It should be noted that according to the Iranian Census data, the number of meningitis cases in the urban population is higher due to the higher population than the rural.

Also, the number of underreported cases in some provinces of the country indicates a severe weakness in the reporting system, which needs to strengthen the syndromic care system and increase regular training to health professionals in identifying and reporting suspected cases. Another critical issue is the lack of up-to-date information so that access to information is delayed.

Although we see a decrease in the number of cases in many provinces due to the small number of cases and geographical distribution of the confirmed cases of meningitis caused by *Haemophilus influenzae* (based on GIS software) the obtain results is very fragile and small variations in the number of cases cause changes in the geographical distribution.

Conclusions

Considering that the number of meningitis cases caused by *Haemophilus influenzae type b* has changed before and after vaccination and the number of meningitis cases has decreased after vaccine integration, so the continuation of pentavalent vaccination is necessary. Since *Pneumococcal pneumonia* is one of the significant causes of meningitis, adding a pneumococcal vaccine to the routine vaccination cycle of the country is also essential.

Declarations

Ethics approval and consent to participate

The study was provided ethical approval by the Hamadan University of Medical Sciences IR.UMSHA.REC (Grant No: 9710186173).

Consent for publication

Not applicable.

Availability of data and materials

The dataset of the current study is available from the corresponding author at a reasonable request.

Competing interests

Authors have no conflicts of interests to declare.

Funding

The study was partially funded by Vice-chancellor for Research and Technology, Hamadan University of Medical Sciences (No. 9710186173). Funding body of this study did not play any role in the design of the

study and collection, analysis, and interpretation of data and in writing the manuscript.

Authors' Contribution

All authors have approved the manuscript. MK has established first idea data analysis and drafted manuscript, SH, SMZ, IS and FAZ helped to design and conduct the study. MK, SH, SMZ, IS and FAZ have had substantial contribution in data gathering, manuscript drafting, and critical revision of manuscript and data analysis. All authors have read and approved the manuscript.

Acknowledgements

The authors are going to thank the Deputy for Research and Technology of Hamadan University of Medical Sciences for supporting the present study and for administering the data with the Ministry of Health. This article is taken from the thesis of Master of Science in Epidemiology of Hamadan University of Medical Sciences (9710186173).

References

1. Berangi Z, Karami M, Mohammadi Y, Nazarzadeh M, Zahraei SM, Javidrad H, Heidari S. Epidemiological profile of meningitis in Iran before pentavalent vaccine introduction. *BMC Pediatr*. 2019;19(1):370.
2. Faryadres M, Karami M, Moghimbeigi A, Esmailnasab N, Pazhouhi K. **Levels of alarm thresholds of meningitis outbreaks in Hamadan province, west of Iran.** *Journal of research in health sciences* 2015, 15.
3. Lewis R, Nathan N, Diarra L, Belanger F, Paquet C. Timely detection of meningococcal meningitis epidemics in Africa. *The Lancet*. 2001;358(9278):287–93.
4. disease WHOM. <https://www.who.int/emergencies/diseases/meningitis/en/>.
5. Rossi PG, Mantovani J, Ferroni E, Forcina A, Stanghellini E, Curtale F, Borgia P. Incidence of bacterial meningitis (2001–2005) in Lazio, Italy: the results of a integrated surveillance system. *BMC Infect Dis*. 2009;9(1):13.
6. Chinchankar N, Mane M, Bhave S, Bapat S, Bavdekar A, Pandit A, Niphadkar K, Dutta A, Leboulleux D. Diagnosis and outcome of acute bacterial meningitis in early childhood. *Indian pediatrics*. 2002;39(10):914–21.
7. Dash N, Ameen AS, Sheek-Hussein MM, Smego RA Jr. **Epidemiology of meningitis in Al-Ain, United Arab Emirates, 2000–2005.** *International journal of infectious diseases* 2007, **11**(4):309–312.
8. Eskola J, Käyhty H, Takala AK, Peltola H, Rönöberg P-R, Kela E, Pekkanen E, McVerry PH, Mäkelä PH. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive *Haemophilus influenzae* type b disease. *N Engl J Med*. 1990;323(20):1381–7.

9. Organization WH. **Measuring impact of Streptococcus pneumoniae and Haemophilus influenzae type b conjugate vaccination.** 2012.
10. Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV, Group BMS. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. *Journal of infectious diseases.* 1990;162(6):1316–23.
11. Kaninda A-V, Belanger F, Lewis R, Batchassi E, Aplogan A, Yakoua Y, Paquet C. Effectiveness of incidence thresholds for detection and control of meningococcal meningitis epidemics in northern Togo. *Int J Epidemiol.* 2000;29(5):933–40.
12. Gupta SK, Sosler S, Lahariya C. Introduction of Haemophilus influenzae type b (Hib) as pentavalent (DPT-HepB-Hib) vaccine in two states of India. *Indian pediatrics.* 2012;49(9):707–9.
13. Lee EH, Corcino M, Moore A, Garib Z, Peña C, Sánchez J, Fernández J, Feris-Iglesias JM, Flannery B. Impact of Haemophilus influenzae type b conjugate vaccine on bacterial meningitis in the Dominican Republic. *Revista panamericana de salud Pública.* 2008;24:161–8.
14. Lewis RF, Kisakye A, Gessner BD, Duku C, Odipio JB, Iriso R, Nansera D, Braka F, Makumbi I, Kekitiinwa A. Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. *Bull World Health Organ.* 2008;86:292–301.
15. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. *Clin Microbiol Rev.* 2000;13(2):302–17.
16. Pindyck T, Tate JE, Bonkougou IJO, Armah G, Mujuru HA, Rugambwa C, Mwenda JM, Parashar U. Timeliness of rotavirus vaccination at sentinel sites in four early-adopter African countries. *Vaccine.* 2019;37(40):6002–7.
17. National Committee on Immunization MoHaME. Schedule and Guideline of Immunization. Tehran: United Nations Children's Fund (UNICEF): Zarak Company;; 2015.
18. Susarla SK, Gupta M, Mantan M, Dhongade R, Bhave S, Das RK, Ray RK, Ramesh Babu T, Ravi MD, Krishnamurthy B, et al. Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6–8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study. *Vaccine.* 2019;37(36):5452–9.
19. Azevedo LCP, Toscano CM, Bierrenbach AL. Bacterial meningitis in Brazil: baseline epidemiologic assessment of the decade prior to the introduction of pneumococcal and meningococcal vaccines. *PloS one.* 2013;8(6):e64524.
20. Karami M, Soori H, Mehrabi Y, Haghdoost AA, Gouya MM. Real time detection of a measles outbreak using the exponentially weighted moving average: does it work? *Journal of research in health sciences.* 2012;12(1):25–30.
21. Raeisi A, Zahraei M, Sorosh najaf abadi M, Shirzadi Mr, Sedaghat A, Masoomi asl H, Nasehi M, Nabavi M. *Comprehensive Handbook of Infectious Diseases Care System for Family Physicians.* Tehran: Andishmand; 2012.

22. Pazhouhi H, Karami M, Esmailnasab N, Moghimbeigi A, Fariadras M. **Temporal patterns of meningitis in Hamadan, Western Iran: Addressing and removing explainable patterns.** *Archives of Clinical Infectious Diseases* 2016, 11(3).

Figures




Figure 1

Time trend of the number of confirm cases of meningitis caused by Haemophilus influenzae type b




Figure 2

Geographical distribution of probable and confirm incidence of meningitis by incidence (in a population of 100,000) prior to pentavalent vaccine administration




Figure 3

Geographical distribution of probable and confirm incidence of meningitis by incidence (in a population of 100,000) after pentavalent vaccine administration